NCT05223088 2025-03-18
Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IVăLarge Borrmann III Type and Bulky N Positive Advanced Gastric Cancer
Fujian Cancer Hospital
Phase 2 Completed
Clinical Trials
10 trialsNCT03228043 2024-11-14
Apatinib for Resectable Colorectal Cancer
Nanchong Central Hospital
Phase NA Withdrawn
NCT03397199 2020-04-15
Study of Apatinib Plus S-1 as the Therapy of Advanced Colorectal Cancer
Henan Cancer Hospital
Phase 2 Unknown
NCT04174339 2019-11-22
PD-1 Antibody(SHR-1210) Plus Apatinib Combined With POF in Advanced Gastric Cancer
Fujian Cancer Hospital
Phase NA Unknown
NCT03954756 2019-05-17
Exploratory Clinical Study of Apatinib and PD-1 in Treating Advanced Gastric Cancer
Henan Cancer Hospital
Phase 2 Unknown
NCT03950141 2019-05-15
Apatinib Combined With S-1 as Maintenance Therapy for HER-2 Negatived Gastric Cancer
Beijing Hospital
Phase 2 Unknown
NCT02697838 2018-10-17
Clinical Trial of Apatinib Reverses Chemotherapy-Resistance of Patients With Advanced Gastric Cancer
Fujian Cancer Hospital
Phase 2 Unknown
NCT03599778 2018-07-26
XELOX Combined With Apatinib as Post-operative Chemotherapy in Locally Advanced Gastric Adenocarcinoma
Anhui Provincial Hospital
Phase 1/2 Unknown
NCT03170310 2017-05-31
Apatinib Treatment for Advanced Esophagus Cancer
Henan Cancer Hospital
Phase 2 Unknown
NCT03030937 2017-01-25
Clinical Trial to Compare Apatinib Plus Irinotecan Versus Single Irinotecan as Second-line Treatment in AGC or EGJA
Fujian Cancer Hospital
Phase 2 Unknown